Consolidated net sales for the third quarter of the fiscal year ending March 2026 increased 3.7% year-over-year to \u00a52,911,667 million, operating income decreased 4.8% to \u00a543,183 million, and net income attributable to owners of parent increased 3.2% to \u00a537,414 million.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7459","jir_company_name":"Medipal Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/7459-20260209-01.pdf","jir_short_summary":"Consolidated net sales for the third quarter of the fiscal year ending March 2026 increased 3.7% year-over-year to \u00a52,911,667 million, operating income decreased 4.8% to \u00a543,183 million, and net income attributable to owners of parent increased 3.2% to \u00a537,414 million.","jir_summary":"### Summary of Business Results\nFor the third quarter of the fiscal year ending March 2026, consolidated net sales increased 3.7% year-over-year to \u00a52,911,667 million, driven by higher sales in the pharmaceutical wholesale business for ethical drugs as well as cosmetics, daily necessities, and OTC pharmaceutical wholesale businesses. On the other hand, operating income decreased 4.8% year-over-year to \u00a543,183 million due to increased expenses in business investments, human resources, and logistics. Ordinary income rose 8.1% year-over-year to \u00a561,313 million, supported by increased investment income, and net income attributable to owners of parent also grew 3.2% to \u00a537,414 million.\n\n### Summary of Financial Position and Others\nTotal assets increased \u00a5194,387 million compared to the end of the previous fiscal year, reaching \u00a52,019,371 million, primarily due to growth in current assets. Liabilities increased \u00a5168,406 million mainly due to higher notes payable and accounts payable. Net assets increased \u00a525,980 million to \u00a5783,927 million. Share buybacks and cancellations were completed by the end of November 2025 and their impact has been reflected in the earnings forecast for the fiscal year ending March 2026. Corporate activities such as acquisition of shares in consolidated subsidiaries are also progressing.","jir_financial_highlights":"Net Sales: 2,911,667 million yen (3.7% increase year-over-year)\nOperating Income: 43,183 million yen (4.8% decrease year-over-year)\nOrdinary Income: 61,313 million yen (8.1% increase year-over-year)\nNet Income Attributable to Owners of Parent: 37,414 million yen (3.2% increase year-over-year)\nEquity Ratio: 31.8% (2.1 points decrease year-over-year)\nNumber of Shares Outstanding (End of Period): 215,975,042 shares (3,251,000 shares decrease year-over-year)","jir_category":"","jir_hashtags":"#MedipalHoldingsCorporation, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a52,911,667 million (3.7% increase year-over-year)\nOperating Income: \u00a543,183 million (4.8% decrease year-over-year)\nNet Income Attributable to Owners of Parent: \u00a537,414 million (3.2% increase year-over-year)","jir_meta_title":"Medipal Holdings Corporation Fiscal Year March 2026 Third Quarter Financial Results Net Sales Up 3.7%","jir_meta_description":"Medipal Holdings Corporation's Fiscal Year March 2026 third quarter financial summary. Net sales reached \u00a52,911,667 million (up 3.7% year-over-year), operating income decreased to \u00a543,183 million (down 4.8%), and net income attributable to owners of parent increased to \u00a537,414 million (up 3.2%).","jir_og_title":"Medipal Holdings Corporation Announces Third Quarter Fiscal 2026 Financial Results","jir_og_description":"Net sales increased 3.7% year-over-year to \u00a52,911,667 million, operating income declined 4.8% to \u00a543,183 million. Ordinary income rose 8.1% to \u00a561,313 million due to increased investment income.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[2807172,2911667],\\\"backgroundColor\\\":\\\"#4e73df\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[45372,43183],\\\"backgroundColor\\\":\\\"#1cc88a\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[36238,37414],\\\"backgroundColor\\\":\\\"#f6c23e\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Net Sales Composition Ratio Q3 2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Wholesale Business for Ethical Drugs\\\",\\\"Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business\\\",\\\"Animal Pharmaceuticals and Food Processing Raw Materials Wholesale and Related Businesses\\\"],\\\"datasets\\\":[{\\\"data\\\":[1875064,950636,88985],\\\"backgroundColor\\\":[\\\"#4e73df\\\",\\\"#1cc88a\\\",\\\"#36b9cc\\\"]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Trend of Gross Profit Margin and Operating Profit Margin (%)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 2025\\\",\\\"Q3 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Profit Margin\\\",\\\"data\\\":[6.92,6.84],\\\"borderColor\\\":\\\"#4e73df\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Operating Profit Margin\\\",\\\"data\\\":[1.62,1.48],\\\"borderColor\\\":\\\"#1cc88a\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false,\\\"min\\\":0,\\\"max\\\":8}}}}\"}]","ir_related_company":7774,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-26083","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n